White matter lesions as explained by a neurologist

Written in association with: Professor Hedley Emsley
Published: | Updated: 12/11/2024
Edited by: Emma McLeod

After receiving a brain MRI scan that show white matter lesions in the form of white spots, you’ll likely have lots of questions. Professor Hedley Emsley (a consultant neurologist) explains what white matter lesions of the brain are, the range of potential causes, if they can cause problems, and more.

A medical professional pointing at specific parts of a brain scan result

My brain scan report mentions white matter lesions – what are these?

White matter lesions are an example of an incidental finding on a brain scan.

 

What are incidental findings?

These are findings on a brain scan that are unrelated to the reason the scan has been requested. For example, brain scans are sometimes done because a patient is seeking reassurance that there is no sinister cause for their headache. Brain scans requested in this situation can be reassuring but they may show ‘unexpected’ or incidental findings.

 

Ideally, it is good to be aware of the possibility of incidental findings being identified before having a brain scan.

 

What are white matter lesions?

White matter lesions affect the white matter . White matter is the deepest part of the brain that contains millions of nerve fibres connecting other parts of the brain and spinal cord. The nerve fibres are surrounded by a fatty material called myelin. This protects the nerve fibres and gives white matter its colour.

 

Deterioration of the white matter happens with ageing and can be seen on brain scans as white matter lesions (abnormal areas). These appear as bright areas or white matter ‘hyperintensities’ on some brain MRI scans. White matter lesions are one of the most common incidental findings on brain scans. White matter lesions might be referred to as age-related, ‘wear-and-tear’ changes.

 

Do white matter lesions cause any problems?

Very often, white matter lesions don’t cause any noticeable problems for the individual. Sometimes, white matter disease, particularly when it is severe, can interfere with the way the brain works and the processes that it controls, including thinking and walking. This is because the nerve signals can’t get through as normal.

 

How common are white matter lesions?

White matter lesions are much more common in older or elderly people. Some studies have found that white matter lesions tend to be seen on the majority of brain scans in older adults but are far less frequently seen on brain scans in younger people.

 

What causes white matter lesions?

Lots of different diseases, as well as injuries and toxic substances, can cause damage to the white matter. High blood pressure (hypertension ) is a very common cause. Other causes include diabetes mellitus, high cholesterol and smoking. Other factors such as genetics are likely to play a role. Sometimes, white matter lesions are caused by inflammation of the brain.

 

My brain scan report mentions small vessel cerebrovascular disease. What is this?

Damage to the very small blood vessels in the brain can cause white matter lesions. This is typically the case when high blood pressure or diabetes mellitus are thought to be the cause of the brain scan changes.

 

The report says the small vessel disease is mild, moderate or severe. What does this mean?

This refers to how many white matter lesions there are and whether they are becoming joined up, or confluent. Very often, people won’t notice any symptoms even if the small vessel disease is severe, but it is wise to ensure that any possible underlying causes are identified to try to prevent the situation getting worse.

 

My report mentions ‘non-specific’ white matter lesions. What are they?

Very often, white matter lesions are ‘non-specific’ and their appearance doesn’t suggest any particular underlying cause. Non-specific white matter lesions are sometimes seen in people with migraine.

 

How are white matter lesions treated?

There is no specific treatment for white matter lesions. It is sensible to make sure that treatable conditions such as high blood pressure are recognised and treated in case the white matter lesions are due to this. It is sensible to make sure conditions such as diabetes mellitus and high cholesterol are under control. If you smoke, it is sensible to stop.

 

Contact Professor Emsley to learn how he can help you with the diagnosis and management of a wide variety of neurological conditions.

By Professor Hedley Emsley
Neurology

Professor Hedley Emsley is a renowned consultant neurologist practising privately at the Greater Lancashire Hospital in Preston. His areas of expertise include vascular neurologystrokecerebrovascular disease (including small vessel disease, cerebral amyloid angiopathy)late-onset epilepsymigraine and neurological disorders including Parkinson’s disease.

Professor Emsley graduated with an MBChB in 1996 from the University of Manchester. He undertook several junior doctor posts in the North West of England and at the National Hospital for Neurology and Neurosurgery in London before becoming a member of the Royal College of Physicians of London (MRCP) in 1999. He then completed a PhD on inflammation and cytokine regulation in stroke, awarded in 2004, and undertook specialist training as a clinical lecturer in neurology at the Walton Centre for Neurology & Neurosurgery in Liverpool. Before becoming a fellow of the Royal College of Physicians of London (FRCP) in 2012, he obtained both the Certificate of Completion of Training (CCT) in neurology and a postgraduate certificate in clinical education in 2008 (PGCTLCP with distinction). He was made a fellow of the Higher Education Academy (FHEA) in 2012.

Professor Emsley was appointed Consultant Neurologist with special interest in Stroke Neurology at Lancashire Teaching Hospitals NHS Foundation Trust in 2008, and in 2014, he became the Clinical Director for Neurology at the Trust for three years. He has numerous external responsibilities including his current roles on the Epilepsy Research Institute’s Mortality, Morbidity and Risk Task Force, the Association of British Neurologists Advisory Group on Data and Devices, and on the Health Data Research UK (HDR-UK) North Executive Committee. Previous roles include co-chair for the Association of British Neurologists Stroke Advisory Group, clinical advisor to the Neurology Intelligence Collaborative, North West National Institute for Health Research (NIHR) advisory panel member for the Research for Patient Benefit (RfPB) programme, and external examiner for the University College London Stroke MSc programme.

He took up his post as Professor of Clinical Neuroscience at Lancaster University in 2017 alongside his NHS role. He has authored or co-authored more than 200 academic outputs in all including articles in peer-reviewed medical journals, reports, book chapters and conference abstracts. He regularly engages in peer-review and editorial work. He is a chief investigator and a research supervisor on a range of NIHR portfolio studies in stroke and neurological disorders. He has extensive research collaborations and a number of research interests including cerebrovascular disease and its interface with other neurological disorders, inflammation, infection, novel mechanisms, targets, biomarkers and trials in cerebrovascular disease and other neurological disorders, as well as novel uses of routinely collected data. He also serves on Lancaster University’s Research Ethics Committee.

Current collaborations and projects include:

  • work with academic partners on NHS England’s North West Secure Data Environment, a secure data and research analysis platform, including funding to support work on artificial intelligence related work on routinely collected data
  • a collaboration with the Department of Health & Social Care using Hospital Episodes Statistics Data on neurological admissions, comorbidities, including work that has highlighted the prominence of cardiovascular disease as a comorbidity in epilepsy
  • a forthcoming book chapter on Epilepsy in Older Adults in the new edition of leading reference in the field of geriatric care, Brocklehurst's Textbook of Geriatric Medicine and Gerontology
  • establishment of a Collaboration for Late Onset and Vascular Epilepsy Research (CLOVER) in the UK and with international partners
  • work as part on the International Small Vessel Disease Network led by the University of Edinburgh to improve clinical SVD care

View Profile

Overall assessment of their patients


  • Related procedures
  • Botulinum toxin (Botox™)
    Neuropsychology
    Sleep disorders
    Learning disabilities
    Tinnitus
    Obstructive sleep apnea
    Neurological treatments
    Chronic headache
    Neuropathic pain
    Epilepsy
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.